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PERSPECTIVES ON DRUGS 
Health responses to new  
psychoactive substances
Initial responses to NPS availability in Europe have largely 
been regulatory, focusing on their supply using legislative 
tools but, as the phenomenon evolves, it has increasingly 
become a priority to formulate and implement effective public 
health responses. This analysis takes a look at some of the 
key risk groups among which NPS are being used and the 
health responses currently being employed across various 
intervention settings.
I  Responding to NPS
The emergence of numerous new psychoactive substances 
(NPS) on the global drug market over the last decade and 
reports of problems associated with their use, represents a 
significant challenge to drug policy and practice (UNODC, 
2013, EMCDDA, 2015a). While prevalence levels of NPS 
use remain low in the general European population, there 
is concern about problematic forms of use and harms in 
particular risk groups across different health and social 
settings. This includes concerns around use among young 
people, participants in nightlife environments, men who have 
sex with men (MSM), people who inject drugs, and prison 
populations. In terms of drug demand reduction interventions, 
these populations can be accessed through a range of health 
and social services including prevention activities, acute care 
management, drug treatment and harm reduction.
This analysis takes a look at the health responses currently 
being employed across various intervention settings where 
users of NPS may seek help or where harms or risk behaviours 
associated with NPS have been reported. These settings 
include schools, nightlife venues, sexual health services, 
The emergence of new psychoactive 
substances (NPS) over the last decade 
has posed a major challenge to drug 
policy. While the limited available data 
indicates that prevalence levels of NPS 
use are relatively low in the general 
European population, there are concerns 
around more problematic forms of use 
and harms in particular drug using 
populations. A number of public health 
concerns have arisen as a consequence of 
their use, although the real extent of these 
harms across Europe remains unknown. 
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emergency and clinical services, low-threshold services, 
specialised drug treatment settings and custodial settings. 
I  School settings
Schools are the most common setting for delivery of drug 
prevention and education in the EU (EMCDDA, 2015b), 
and whilst there is a developing evidence base for effective 
approaches and programmes, these activities tend to be 
focused on drugs such as cannabis, or target substance-
related risk factors and harms in general (EMCDDA, 2015c; 
Faggiano et al., 2014).
As NPS prevalence is low in the school age population 
(European Commission, 2014), universal approaches, 
which target all students regardless of their level of risk of 
NPS use, are unlikely to be cost-effective. If concerns due 
to NPs use among some students arise, existing prevention 
programmes may be adapted to include NPS. However, it is 
important that these are only delivered as part of a carefully 
monitored and evaluated programme, as a number of 
existing drug prevention programmes and approaches have 
been evaluated as being ineffective or even associated with 
negative consequences (e.g. standalone mass media and 
information campaigns). It is therefore recommended that 
school-based NPS-related prevention activities should only be 
delivered as part of generic prevention programmes for which 
there is evidence of effectiveness. Evidence-based resources 
such as the European Drug Prevention Quality Standards 
(Brotherhood and Sumnall, 2011) and other tools (UNODC, 
2013) may prove useful in the development and refinement of 
such NPS-related prevention activities in schools.
I  Nightlife settings
A range of health responses to drug use and related harms 
have been applied to nightlife settings such as bars, pubs, 
nightclubs, discotheques or music festivals. These include 
changes to the physical environment (e.g. chill out rooms, 
crowd control, better ventilation), the provision of information, 
education, outreach, drug checking and crisis management.
There are a growing number of examples of both on- and 
off- site drug checking services across Europe which provide 
the chemical analysis of drugs which have been submitted 
for testing by users. Such facilities are presented as an 
opportunity for users to make an informed decision about their 
intended drug use, and some service providers also make the 
most of the interaction to offer personalised advice and harm 
reduction information, screening and brief interventions (TEDI, 
2013). However, there is a need for a better understanding of 
the optimal content, framing, and targeting of communication 
about potentially harmful drugs, including NPS. Data from 
testing may also be directed to policymakers and health 
professionals such as emergency medical professionals 
who may benefit from information on the nature of drugs in 
circulation in their geographical area. The aims and impact of 
nightlife health responses are not always sufficiently defined 
or evaluated, and there is limited information on NPS-specific 
responses in nightlife settings.  However, health responses 
and interventions aimed at established drugs and alcohol in 
nightlife settings are relevant and may be adapted to respond 
to NPS use and related harms (e.g. the EU Healthy Nightlife 
Toolbox; EMCDDA Best practice portal entries on partygoers 
and nightlife).
I  Emergency and clinical services
Despite limited understanding of the acute toxicity of 
many NPS, difficulties in identifying substances consumed 
(i.e. through self-report or toxicological screening), and 
the high proportion of polysubstance use, staff working in 
emergency settings have been required to develop acute 
care management and best practice protocols in response to 
an increasing number of NPS-related presentations. Clinical 
management is generally orientated towards providing 
symptomatic care, as NPS toxicity is likely to be similar to that 
produced by drugs in equivalent pharmacological classes 
(Dines et al., 2015). However, there are notable exceptions, 
such as the dissociative methoxetamine, which illustrate gaps 
in current clinical understanding. Whilst most NPS-related 
cases will be discharged within a few hours of presentation, 
there may be opportunities for medical staff to provide 
screening, brief advice, and referrals to community support. 
Opportunities for emergency care and support are not just 
limited to hospital settings. On-site medical support plays 
an important role in multidisciplinary outreach responses 
in nightlife and festival settings and guidelines have been 
developed to improve pre-hospital management and 
identification of individuals that require immediate hospital 
assessment by nightlife medical staff (Euro-DEN, 2015).
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I  Sexual health settings  
Increasing evidence is becoming available on how men who 
have sex with men (MSM) are using synthetic cathinones, 
such as mephedrone, alongside traditional stimulants, for 
sexual purposes (Bourne et al, 2014). This is often referred 
to as ‘chemsex’. Studies also report injection of cathinones 
(and other stimulants) among MSM during sexual practices 
known as ‘slamming’, with a high risk of infections of both HIV 
and Hepatitis C linked to sharing of injecting material. There 
exist several barriers to MSM with drug problems accessing 
services. These include stigma, a lack of cultural competence 
among traditional drug service providers, MSM not self-
identifying their drug use as problematic, a lack of awareness 
of available drug services among MSM, and a lack of specific 
services for the use of chemsex drugs. A preference for 
MSM to engage with sexual health services and a need for 
combined sexual health and drug interventions, has led 
some countries to focus on the development of joint drug 
and sexual health services targeted at this population. With 
regards to reducing harms associated with the sexual risk 
behaviour involved in chemsex, specialist support services 
for MSM with HIV may also be useful in order to reduce 
harms and prevent the transmission of HIV and other sexually 
transmitted infections. However, there is currently a lack 
of data on use and harms among this population to inform 
appropriate harm reduction services, and a lack of evaluation 
of the effectiveness of the approaches used (Bourne et 
al., 2015). Guidance for clinicians in responding to the use 
and associated harms of drugs for chemsex purposes is 
provided by the Novel Psychoactive Treatment UK Network 
NEPTUNE (Abdulrahim et al., 2016). This guidance suggests 
that regardless of setting, the provision of clear, honest and 
non-judgemental advice on chemsex and information on how 
to manage potential harms should be delivered by culturally 
competent individuals with an understanding of how cultural 
issues influence patterns of drug use and harms in this 
population.
I  Low-threshold settings
Low-threshold services provide support for drug users 
on a regular basis, and frequently deliver harm reduction 
activities such as needle exchange, advice, information and 
assistance relating to housing, hygiene, and sexual health. 
Given a lack of data on the use, harms, and effectiveness 
of low-threshold responses to NPS, existing effective 
approaches in reducing drug use and associated harms in 
this setting may be adapted to incorporate NPS. In general, 
low-threshold and harm reduction activities for NPS will 
mirror those delivered to people who take established drugs 
but there are additional considerations with respect to the 
injection of NPS as these users may be at an increased risk 
I  Facts and figures 
The 2014 Flash Eurobarometer on young people and 
drugs, a telephone survey of 13 128 young adults aged 
15–24 in the 28 EU Member States, found that 8 % of 
respondents reported lifetime use of ‘new substances 
that imitate the effects of illicit drugs such as cannabis, 
cocaine, ecstasy, etc.’, with 4 % reporting use in the last 
year
An analysis based on the 2014 internet-based Global 
Drug Survey data on drug use among young adults who 
self-identified as regular nightclub goers showed that 
the most common NPS self-reported to have been used 
last year were ketamine (11 %), mephedrone (3 %), 
synthetic cannabinoids (3 %) and GHB (2 %). Overall, 
self-reported NPS use was on average much lower than 
self-reported use of so-called ‘club drugs’ such as ecstasy, 
amphetamines and cocaine (EMCDDA, 2015b).  
 
A recent French survey revealed that 4 NPS users in 10 
experience adverse effects following use, yet fewer than 
4 % of them seek support from a health professional 
(Cadet-Taïrou, 2016).
‘Chemsex’ is defined as sex between men that occurs 
under the influence of drugs taken immediately preceding 
and/or during the sexual session and is associated with 
high-risk sexual behaviours and sexually transmitted 
infections (Bourne et al., 2014). A survey of HIV-positive 
patients attending 30 HIV clinics in England and Wales, 
found that nearly a third (29 %) of MSM patients reported 
engaging in ‘chemsex’ in the past year and that one in ten 
reported ‘slamming’ (Pufall et al., 2016).
In Hungary, nearly 70 % of people who inject drugs 
and visit low-threshold services report to be primarily 
injecting synthetic cathinones (Tarján, 2015). Injecting 
of cathinones is associated with high frequency and 
compulsive injecting, needle sharing, changes in injecting 
behaviours (e.g. groin injecting) and increased high risk 
sexual behaviours, with a risk for increased HIV and 
Hepatitis B transmission (Hedrich et al., 2013, Sarafis and 
Tsounis, 2014, Giese et al., 2015; Rácz et al., 2015).
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of harm due to the exposure to novel drugs with uncertain 
psychopharmacological and toxicological profiles. Whilst 
most NPS injectors are thought to have a history of opiate 
or amphetamine injection and therefore may already 
possess some harm reduction knowledge, it should not 
be assumed that this is sufficient to protect against novel 
harms associated with injecting NPS. The provision of 
sterile injection equipment/kits and condoms, and the 
dissemination of information on safe injecting among NPS 
injectors is important, although needle and syringe exchange 
programmes may need to adapt to the differing injection 
practices of stimulant injectors (e.g. more frequent injections). 
One example where specific low-threshold staff competence 
is already applied to reduce NPS-related harm is the EU-
funded Local PASS project.  Here, peers and (other) low-
threshold staff collaborate as partners of a Local Emerging 
Drug Trend Panel in identifying new substances, risk groups 
and settings and by grading the risks. The Local Panel then 
takes a decision about the relevant interventions, according to 
type and risk level (http://www.localpass.eu/cms/local-pass-
toolkit/). Where NPS injecting is observed in some Member 
States, increasing the accessibility and provision of sterile 
injecting equipment and the opportunity for blood borne virus 
testing in specialist services and community environments 
has been prioritised, as well as raising awareness of the risks 
of injection, particularly infection with HIV and Hepatitis C.
I  Specialised drug treatment settings
Structured drug treatment responses to NPS may in 
many respects resemble those offered to clients using 
drugs from similar pharmacological classes. There are 
currently no maintenance or substitute pharmacotherapies 
available for people with problematic NPS use, and with the 
exception of GHB/GBL, few recommendations for specific 
pharmacological management of withdrawal have been 
developed. The NEPTUNE guidelines (see box) suggest that 
the nature and intensity of the treatment offered should 
be related to the severity of the NPS problem with an 
assessment of the client’s health and other consequences 
of use. Some clients presenting to treatment services may 
benefit from low intensity brief interventions based on 
general or tailored advice and even those showing NPS-
related harm may benefit most from self-help approaches 
rather than referral to a structured intervention. Where 
problematic or high risk NPS use has been identified, 
individual/ group-based behavioural and psychosocial 
approaches (e.g. cognitive behavioural therapy, motivational 
interviewing, community reinforcement, and contingency 
management) or formal psychological therapies, delivered as 
part of a staged or stepped care approach, may be effective. 
Therefore, a thorough assessment of NPS use, consequences 
of use, and related needs is essential in such cases. It is also 
important that treatment provider competencies include the 
skills needed to screen, assess, and treat NPS problems; 
the provision of support to develop expertise on NPS (e.g. 
training on broad classes of drugs, effects, and harms); the 
development of ‘cultural competencies’ to work with a wide 
range of client groups; the identification of clear pathways 
to more specialised support for complex cases; and the 
establishment of networks to share evidence, develop 
guidelines, and facilitate professional development.
Demand for specialist treatment related to NPS problems 
in Europe remains limited, potentially reflecting overall 
low prevalence levels. However, increases in demands for 
specialist treatment related to problem use of synthetic 
cathinones are reported from France, Ireland, Poland, 
Romania and the United Kingdom (EMCDDA, 2016).
Findings from a European study (EURO-DEN) collecting 
annual data on all acute drug toxicity presentations to 
hospital emergency rooms in sixteen sentinel centres in 
10 European countries showed that from a total of 5 529 
presentations involving drugs, NPS represented 5.6 % of 
all acute emergencies, with mephedrone and methedrone 
being the most common (Dines et al., 2015). NPS-related 
symptoms were frequently associated with typical 
stimulant- or hallucinogen-like features which mostly 
included agitation, aggression, anxiety, palpitations and 
hallucinations.
A recent survey in English prisons found that synthetic 
cannabinoids were reported by 10 % of surveyed inmates 
and as the second most commonly used drug while in 
prison, after herbal cannabis (13 %). The use of synthetic 
cannabinoids in prisons is reported to be associated with 
increasing medical emergencies, deaths, bullying, violence 
and debt (HM Inspectorate of Prisons, 2015a and b).
Five videos focusing on different settings and the responses to NPS, available on 
the EMCDDA website:  
www.emcdda.europa.eu/topics/pods/health-responses-to-nps      
I  Interactive element: videos
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I  Prisons and custodial settings
With a lack of data on the use, nature, harms and 
effectiveness of responses to NPS use among the prison 
population, existing effective approaches in reducing drug 
use and associated harms among the prison population may 
be adapted to incorporate NPS. For NPS users who may also 
be consuming opioids and injecting NPS, existing evidence 
supports the prescription of opioid substitution treatment 
to reduce mortality and risky drug injecting behaviours in 
prison. Moreover, psychosocial treatment has been found 
to be effective in reducing reincarceration. However, due to 
an overall lack of research and information available on how 
to respond to NPS in custodial settings, it remains unclear 
as to whether such responses help prevent risky practices 
associated with NPS use in this setting.
Partnerships between prison health services and providers in 
the community may prove particularly important in supporting 
the delivery of health education and treatment interventions 
for NPS use and harms in prisons and in ensuring continuity 
of care upon prison entry and release. A toolkit for prison staff 
on the management of NPS-related health problems has 
been developed in the UK (1).
I Conclusion
The NPS market is complex and the rapid emergence 
of novel products means that developing supportive 
health intervention responses is challenging. Existing and 
recommended interventions for NPS use and problems in 
various settings are largely based upon existing responses 
to other drugs. Adaptations of effective interventions 
should ensure that they reflect unique user group needs; 
the structural, cultural and social contexts where NPS are 
taken; new opportunities for engagement of user groups and 
delivery of services; and the requirement for the development 
of specific cultural competencies in those delivering such 
services. However, it is important to acknowledge that existing 
prevention, treatment and harm reduction responses to drug 
use still often lack strong evidence of effectiveness. Therefore, 
adapting these interventions to respond to NPS must proceed 
with caution and within a robust evaluative framework.
Further reading: Health responses to new psychoactive 
substances (EMCDDA, 2016).
(1) www.nta.nhs.uk/uploads/new-psychoactive-substances-in-prisons%5B0%5D.pdf (last accessed June 2016).
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The UK-based NEPTUNE guidance material has been 
developed to improve clinical practice in the management 
of harms resulting from the use of club drugs and novel 
psychoactive substances. It is aimed at clinicians working in 
a range of frontline settings, including drug treatment and 
recovery services, emergency departments, sexual health 
services, primary care and mental health services. It aims 
to improve confidence, competence and skills of clinicians 
and other professionals in the detection, assessment and 
management of the acute and chronic harms associated 
with the use of club drugs and novel psychoactive 
substances. 
 
NEPTUNE specifically addresses the diverse new contexts 
and patterns of use, risk and harms of club drugs and NPS 
(e.g. clubbing, festivals or sexual behaviours). 
 
A number of documents have been developed by NEPTUNE 
to support this process: 
 
Guidance on the Clinical Management of Acute and 
Chronic Harms of Club Drugs and Novel Psychoactive 
Substance 
 
This guidance focuses on the clinical management of acute 
and long terms harms resulting from use of club drugs and 
NPS. The guidance is based on the systematic review and 
critical appraisal of the English language literature. Where 
evidence was lacking, clinical consensus was sought from 
the multi-disciplinary group of expert advisors to the project. 
In order to deal with the ever-growing number of club drugs 
and NPS, NEPTUNE has adapted the following approach: 
 
• Club drugs and NPS are classified, based on their primary 
effects as depressants, stimulants and hallucinogens. 
In addition, the synthetic cannabinoid receptor agonists 
(SCRAs) are treated as a separate category, largely 
for reasons relating to their availability and clinical 
management. 
• The guidance focuses in particular on commonly used club 
drugs and NPS including, but not limited to, GHB, ketamine, 
methamphetamine, mephedrone, MDMA, SCRAs and a 
range of hallucinogens. 
 
http://neptune-clinical-guidance.co.uk/wp-content/
uploads/2015/03/NEPTUNE-Guidance-March-2015.pdf (last 
accessed June 2016) 
 
NEPTUNE Overview and Recommendations on Club Drug 
Use among Lesbian, Gay, Bisexual and Transgender (LGBT) 
People 
 
This overview describes patterns of club drug use and NPS 
use among LGBT populations, as reported in the literature. 
It examines at the factors that may impact on the use of 
substances and discusses drug-related and other harms. 
 
The document also looks in some detail at the use of 
drugs in a sexual context and at the risks associated with 
a particular pattern of drug use and sexual behaviours, 
sometimes referred to as ‘chemsex’, that has been 
particularly associated with risk and harm. The document 
addresses treatment responses to club drug use for MSM 
and is intended to guide improved service and treatment 
planning. 
 
http://neptune-clinical-guidance.co.uk/wp-content/
uploads/2016/02/neptune-club-drug-use-among-lgbt-people.pdf 
(last accessed June 2016) 
 
For more information on NEPTUNE, see: www.neptune-
clinical-guidance.co.uk 
 
 
 
NEPTUNE — Guidance for health professionals responding to NPS use and harms  
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